Table 1.
Characteristics of the generation and validation cohorts.
| Generation cohort (n = 229) | Validation cohort (n = 114) | P-value | |
|---|---|---|---|
| Age at disease onseta (years) | 26.2 (6.3) | 26.4 (6.8) | 0.788d |
| Age at conceptiona (years) | 30.7 (4.9) | 30.4 (6.2) | 0.663d |
| Disease duration at conceptiona (years) | 6.5 (5.1) | 6.6 (6.2) | 0.874d |
| Annualized relapse rate before conceptiona | 0.38 (0.60) | 0.37 (0.68) | 0.889d |
| EDSS before conceptionb | 1 (0–4.5) | 1 (0–5.0) | 0.623e |
| Number of DMTs prior to conceptionb | 1 (0–3) | 1 (0–3) | 0.783e |
| DMT prior to conceptionc | 177 (77.3) | 87 (76.3) | 0.840f |
| Interferon betac | 45 (19.7) | 18 (15.8) | 0.734g |
| Glatiramer acetatec | 33 (14.4) | 19 (16.7) | |
| Dimethyl fumaratec | 19 (8.3) | 12 (10.5) | |
| Fingolimodc | 29 (12.7) | 14 (12.3) | |
| Natalizumabc | 51 (22.3) | 24 (21.1) | |
| Treatment duration before conceptiona (years) | 2.4 (2.9) | 2.3 (3.1) | 0.760d |
| Wash out duration before conceptiona (weeks) | 5.1 (5.8) | 5.3 (6.3) | 0.770d |
| DMT start postpartumc | 160 (69.9) | 81 (71.1) | 0.821f |
| Time until DMT restart postpartuma (weeks) | 19.2 (12.1) | 20.1 (13.2) | 0.530d |
DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale.
a
mean (SD).
b
median (range).
c
absolute number (percentage).
d
independent t-test.
e
Mann–Whitney U test.
f
Fisher's exact test.
g
Chi-squared test.